Tsubota Laboratory Incorporated
Stock Price Chart
2026/10/01 19:14 UpdatedPrice Trend
2026/10/01 19:14 UpdatedPrice & Trading Details
2026/10/01 19:14 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥955M | ¥674M | ¥1,357M | ¥200M |
| Gross Profit | ¥719M | ¥21M | ¥1,177M | ¥132M |
| Operating Income | ¥167M | -¥650M | ¥235M | -¥788M |
| Pretax Income | ¥145M | -¥635M | ¥282M | -¥760M |
| Net Income | ¥90M | -¥641M | ¥206M | -¥762M |
| EPS | ¥3.52 | -¥5.15 | ¥7.92 | -¥29.58 |
| Operating Margin | 17.50% | -96.44% | 17.35% | -393.87% |
| Balance Sheet | ||||
| Total Assets | ¥2,673M | ¥2,295M | ¥2,503M | ¥1,319M |
| Total Equity | ¥1,950M | ¥1,367M | ¥1,587M | ¥864M |
| Total Liabilities | ¥723M | ¥928M | ¥916M | ¥455M |
| Cash | ¥2,161M | ¥1,883M | ¥1,539M | ¥970M |
| Interest-bearing Debt | ¥139M | ¥117M | ¥90M | ¥69M |
| Equity Ratio | 72.97% | 59.57% | 63.41% | 65.50% |
| D/E Ratio | 0.07 | 0.09 | 0.06 | 0.08 |
| Cash Flow | ||||
| Operating CF | ¥28M | -¥301M | -¥318M | -¥578M |
| Investing CF | -¥54M | -¥12M | -¥15M | -¥8M |
| Financing CF | ¥1,012M | ¥36M | -¥12M | ¥17M |
| Free CF | -¥20M | -¥313M | -¥336M | -¥587M |
| Efficiency | ||||
| ROE | 4.62% | -46.91% | 12.96% | -88.19% |
| ROA | 3.37% | -27.94% | 8.22% | -57.77% |
Latest IR Information
-
First Quarter Financial Summary for the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)
Revenue was 215,410 thousand yen, a substantial increase YoY. Operating loss was 170,632 thousand yen, ordinary loss 133,859 thousand yen, and quarterly net loss 134,154 thousand yen. The full-year outlook remains unchanged at 1,100 million yen to 1,500 million yen...
Read more -
Notice Regarding the Recording of External Revenue (Grant Income)
Notice regarding the recording of grant income related to research and development support. There may be confirmations or corrections about the treatment of external revenue within the period.
Read more -
【Tsubota Laboratory】 Achievement of Milestone in Clinical Trial of Myopia Progression Suppression Device | July 2026
Tsubota Laboratory announced the submission of the final clinical trial report for the myopia progression suppression device "TLG-001" and achievement of a milestone. In the fiscal year ending March 2027, a one-time payment is scheduled to be recognized as sales,...
Read more
Latest News (5 items)
Company Information
About
Tsubota Laboratory Incorporated engages in the development and sale of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, presbyopia, and brain diseases in Japan, China, France, and internationally. The company was incorporated in 2012 and is headquartered in Tokyo, Japan.
